MedTrace Logo

Biomarkers for Prognosis of Glioblastoma (GBM)

NCT01493219 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2023-09-14

No results posted yet for this study

Summary

The purpose of this study is:

1. To learn if (MMP-2, MMP-9 and NGAL) which are substances found in blood and urine associated with tumors, can be used as tumor markers in the management and treatment of glioblastoma.
2. To study the relationship between MMP-2, MMP-9 and NGAL with quality of life and disease symptoms.

Conditions

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Nicole A Shonka, MD · University of Nebraska

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-20
Primary Completion
2017-09-01
Completion
2017-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01493219 on ClinicalTrials.gov